Amedisys fine tuning tool to curb re-hospitalization

BATON ROUGE: Amedisys Inc. (Nasdaq: AMED) took its first major step into the world of predictive analytics in August when it announced a minority investment in home health-focused data science firm Medalogix. The Baton Rouge, Louisiana-based company has now started to reap the rewards of that investment.

During the past few months, Amedisys has been fine-tuning its use of Medalogix Touch, a tool designed to slash re-hospitalization rates and keep patients away from the emergency room through its risk stratification and interactive voice response (IVR) capabilities. Amedisys — one of the largest home health, hospice and personal care companies in the country — rolled out the tool as part of a six-month pilot across 43 participating locations.

“With a company this size, piloting something is so important to make sure we work out all the processes and ensure we have a smooth transition,” Carolyn Erskine, assistant vice president of nursing innovation at Amedisys, told Home Health Care News. “Anecdotally, we’ve been getting some good results — and patient feedback has been positive.”

Overall, Amedisys has 472 care centers across 38 states and Washington, D.C. The locations participating in the pilot are scattered throughout all four of its geographic regions, Erskine said.

Medalogix Touch — integrated directly into Amedisys’ electronic medical record (EMR) system — works by analzying historical information to predict which patients are at the highest risk of hospital readmission. The tool uses IVR and automated calling to check up on high-risk patients based on those insights, asking them a handful of key questions to potentially uncover any health-related red flags.

One question, for example, is: “Are you feeling more tired, weak or anxious than usual?”

If any red flags are raised, an Amedisys call center employee then follows up with patients directly and coordinates any necessary in-person clinician visits. So far during the six-month Medalogix Touch pilot, the time between a red flag and an Amedisys follow-up call has been 26 minutes.

“I think patients feel reassured knowing that they’re part of this calling program,” Erskine said. “Clinicians obviously can’t go see patients every day. This calling program gives that patient an opportunity to have another daily ‘touchpoint,’ where we can see how they’re doing.”

After an initial enrollment call to gauge patient interest in the program, the Medalogix Touch platform schedules daily automatic calls for 14 days. Over time, that lessens to three times a week for another two-week period.